PAREXEL APPOINTS SUSAN H. ALEXANDER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL
BOSTON, MA, September 25, 2003 — PAREXEL International Corporation (Nasdaq: PRXL) announced the appointment of Ms. Susan Alexander to the position of Senior Vice President and General Counsel. In her new capacity, Ms. Alexander will oversee the Company's worldwide corporate legal responsibilities including general corporate and legal affairs as well as corporate governance-related activities. Ms. Alexander will be based at PAREXEL’s headquarters in Waltham, Massachusetts.
“Susan brings to PAREXEL an extensive knowledge of corporate law in both domestic and international arenas,“ stated Josef H. von Rickenbach, PAREXEL’s Chairman and CEO. “We welcome Susan to the PAREXEL organization and look forward to working with her to ensure a continued high level of legal leadership and contributions to the Company.”
Ms. Alexander has over twenty years of legal experience in the corporate sector. Prior to joining PAREXEL, Ms. Alexander most recently served as General Counsel and Secretary at IONA Technologies PLC, an international software integration company. She also previously was employed as Counsel at Cabot Corporation, a specialty chemical manufacturer. Prior to moving to the corporate world, she held the position of Partner at the law firms of Fine & Ambrogne and Hinckley Allen & Snyder, where she provided general corporate representation to privately and publicly held companies in a broad range of industries.
Ms. Alexander received her Juris Doctor from Boston University School of Law and earned her Bachelor of Arts degree from Wellesley College.
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 36 countries around the world, and has 5,095 employees.
This release contains "forward-looking" statements. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects" and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2003, as filed with the Securities and Exchange Commission on September 15, 2003, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.